Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

A Randomized, Double-Blind, Parallel Group, Active Controlled, Multi-center Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) 50 mg qd and 100 mg qd in Subjects with Symptoms of Overactive Bladder.
mirabegron
178-CL-049
NCT00688688
Urinary Bladder, Overactive
Phase 3
 
Extension study of 178-cl-046 and 178-cl-047.
February 2015

Powered by ideaPoint, Inc.